PTGFRN

Across TCGA pan-cancer cohorts, PTGFRN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTGFRN data layer compared with 14 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTGFRN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTGFRN expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PTGFRN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.162	1.000	.024	21	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	9	view →
GBM	DFS	Median	All	0.290	0.450	.003	3	view →
LUAD	DFS	Tertile	II,III,IV	0.732	0.951	.024	3	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.904	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTGFRN–CCRCC (DFS)

Open the CCRCC breakdown →